
Please try another search
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Andrew Gottesdiener | 33 | 2023 | Independent Director |
Tomas Kiselak | 38 | 2023 | Independent Director |
Mark C. McKenna | 44 | 2023 | Independent Chairman of the Board |
Michael Thomas Henderson | 35 | 2022 | CEO & Director |
Nimish P. Shah | 46 | 2023 | Independent Director |
Jennifer A. Fox | 53 | 2023 | Independent Director |
Peter Evan Harwin | 39 | 2022 | Independent Director |
William Jones | 61 | 2023 | Independent Director |
Lisa Bollinger | 61 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review